Navigation Links
GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
Date:1/3/2008

Compound 642444 and Compound 685698 advance in clinical development for the

treatment of asthma

LONDON, PHILADELPHIA and SAN FRANCISCO, Jan. 3 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) and Theravance, Inc. (Nasdaq: THRX) today announced the start of large Phase 2b asthma dose-optimization studies with both the lead inhaled corticosteroid (ICS) GW685698 ('698) and the lead long-acting beta agonist (LABA) GW642444 ('444) assets in the 'Horizon' program to develop a next-generation combination product.

GSK began enrolling patients with mild to severe asthma in the '698 Phase 2b clinical program on 21st December 2007 and began enrolling patients with persistent asthma in the '444 Phase 2b clinical program on 29th December 2007. These clinical programs will determine the most effective doses to be taken into Phase 3 combination studies. The Phase 2b COPD program with '444 is also on schedule to commence in 1H 2008.

Darrell Baker, SVP GSK Respiratory Medicines Development Centre said, "The program is progressing well and we are delighted to have two very strong assets to progress into our large Phase 2b studies." He continued, "We have seen encouraging results in previous studies and have confidence in our ongoing program. Both asthma and COPD are serious, debilitating diseases where there remains a considerable unmet need. We believe through this program we will introduce a meaningful option for the treatment of patients with these conditions."

"We are very p
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
2. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
3. GlaxoSmithKline Accelerates Review of Exelixis XL880
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
7. BD Announces FDA 510(k) Clearance of Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures
8. FASgen Announces a New Discovery in Obesity Research
9. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
10. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
11. FASgen Announces New Discovery for Treatment of Stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014   ViaDerma, Inc. (OTCQB: VDRM), ... products to market, has recently released a revolutionary ... a topical liquid tetracycline-based antibiotic that uses a ... oral medication active ingredients into topical drugs. The ... antibiotic to help prevent skin infection in minor ...
(Date:10/30/2014)... CVS Health (NYSE: CVS ) announced ... leading regional health systems to enhance access to high-quality, affordable ... Baptist Health System in Alabama ; Community ... Pennsylvania , Northwest Medical Center, including Oro ... Healthcare in Tennessee ; and Premier Health ...
(Date:10/30/2014)... Kingdom , Oct. 30, 2014 Molecular ... CBRX ) and Maryland ... developers with improved efficiency during clinical development that will ... next week. This partnership extends ... platform, which it launched earlier this month. The company ...
Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 2CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 4Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3
... , March 11 Watson Pharmaceuticals, Inc. ... Food and Drug Administration (FDA) approval of TRELSTAR® 22.5 ... formulation of TRELSTAR®, a proven, simple and effective palliative ... launch, TRELSTAR® 22.5 mg is the first and only ...
... SiteJabber.com , a leading consumer protection service which helps people avoid fraudulent websites and find good sites, and LegitScript.com ... websites and avoid fraudulent ones. , ... ... ...
Cached Medicine Technology:FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 2FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 3FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 4FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 5FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 6FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 7FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 8SiteJabber & LegitScript Launch Partnership to Improve Transparency Around Online Pharmacies 2SiteJabber & LegitScript Launch Partnership to Improve Transparency Around Online Pharmacies 3
(Date:10/30/2014)... treatments for injuries and damage to the joints, including ... is a hard material that caps the ends of ... biomedical engineers, exploring ways to toughen up engineered cartilage ... new developments this week in the journal Proceedings ... problem with engineered tissue is that the mechanical properties ...
(Date:10/30/2014)... Nutrition Leaders, a popular online retailer of ... more, is currently hosting a sweepstakes on its official ... open to U.S. residents age 18 and over, and ... lucky winner will then be selected at random from ... to NutritionLeaders.com. , Nutrition Leaders’ managing director Kimba Vasquez ...
(Date:10/30/2014)... October 30, 2014 Five months after ... Hodgkinson Street LLC announces new branding and a website ... Mepham . After David Mepham’s promotion to name partner ... and website to include Mepham’s name and better reflect ... and mediation firm, the decision to implement new branding ...
(Date:10/30/2014)... Tara Haelle HealthDay ... -- More than 100 genes have been identified that ... report. And researchers say they are on their ... may contribute to the disorder. Autism spectrum disorders ... and social difficulties and repetitive behaviors. An estimated one ...
(Date:10/30/2014)... Francisco, California (PRWEB) October 30, 2014 ... billion by 2020, according to a new study by ... coupled with surging demand for sugar and fat free ... to augment the demand for prebiotics over the forecast ... http://www.grandviewresearch.com/industry-analysis/prebiotics-market , Food & beverage was the ...
Breaking Medicine News(10 mins):Health News:Making lab-grown tissues stronger 2Health News:Nutrition Leaders Announces Gift Card Sweepstakes 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 4Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 5
... aerobic exercise alone is best for lowering blood pressure. Researchers ... difference when it comes time to face the blood pressure ... of vigorous exertion, but exercise as a regular activity is ... the type of exercise// people engaged has made any difference ...
... arms in an accident is getting some high-tech help with ... ,Two years ago, a healthy Jesse Sullivan, 56, was ... a live wire,// costing him both his arms up to ... a traditional artificial prosthesis, relying on chains and buttons to ...
... researchers say eating milk chocolate, which is most commonly ... in the bloodstream. They found the same discouraging result ... ,The results suggest that milk and other dairy ... protective compounds in chocolate. Only subjects who ate dark ...
... SARS virus outbreak contained around the world after removing ... areas. ,SARS is thought to have originated in southern ... November. From China, experts believe the flu-like illness //was ... as far as South Africa and Canada infecting at ...
... of the most widely used disinfectants,for indoor swimming ... due to it's ability to kill Bacteria,efficiently and ... might be the likely reason for the sudden,increase ... culprit is a chemical known as trichloroamine//,(chemical name ...
... off just with the news and then following it ... disrupts their world completely. However, researchers now claim that ... of treating these cancers. Radiation oncologist Frank Vicini, M.D., ... new type of treatment called quadrant irradiation, doctors will ...
Cached Medicine News:Health News:Aerobics- right choice for Cutting Blood Pressure 2Health News:A man who lost both of his arms in an accident 2Health News:When it comes to health, all chocolates not the same. 2Health News:SARS outbreaks contained 2
... System offers strength and radiolucent capabilities ... anteater titanium microdiscectomy system for microscope-aided ... for less invasive procedures with reduced ... to provide low profile, unobstructed retraction ...
Valin Hemilaminectomy Retractor, self retaining with rack and pinion action....
Karlin Crank Frame Spinal Retractor Set is designed for posterior lumbar and thoracic spine surgery. Arm design allows the blades be pre-positioned in the wound prior to attachment....
Circular Spine Retractor System for microsurgical interventions in the lumbar and cervical spine region....
Medicine Products: